This Technology Has Not Been Cleared or Approved by the FDA and Is Not for Sale in the United
See how ABC are framing this — we run every side, so you decide. News for humans, not bots: serious, civil discussion among real people, with the context and facts you need. Don't just watch: be on the air with your own video takes, polls and predictions.
EVERY NETWORK'S FRAMING
“THIS TECHNOLOGY HAS NOT BEEN CLEARED OR APPROVED BY THE FDA AND IS NOT FOR SALE IN THE UNITED”
covered 1d ago ▶ Be on the air with ABCWatch the moment
Add your voice
This storyWhich U.S. agency's clearance did Theranos's technology lack, per the chyron?
- FDA
- FTC
- SEC
- CDC
Guess, then reveal the answer
FDA
Theranos exploited an FDA diagnostic loophole dating to 1976.
The FDA's authority over blood-testing devices stems from the Medical Device Amendments of 1976. Lab-developed tests like Theranos's were long exempt — a gap regulators debated closing for decades before Holmes's company made it urgent.
Topic poll · all networksHow long until this FDA-unapproved technology is cleared for US sale?
A 2025 court struck down FDA's rule on lab-developed tests like Theranos's
FDA finalized the rule in May 2024, ending its decades-long leniency toward in-house lab tests. In March 2025 a Texas federal judge vacated it, and the agency chose not to appeal.
Full FDA device approval can take 3–7 years of clinical review.
The FDA's toughest pathway — Premarket Approval (PMA) — requires extensive clinical trial data proving safety and effectiveness. It costs manufacturers an average of $94 million just to complete the application.
In 2024, the FDA moved to regulate lab tests the way Theranos evaded.
For decades, lab-developed tests dodged FDA device oversight via 'enforcement discretion.' Theranos exploited this gap. The FDA's 2024 rule phases in full LDT oversight over 4 years — a direct policy legacy of the Theranos scandal.